# Expert Assessment: Metabolic Reprogramming for Senolytic/Anti-Senescent Approaches in Neurodegeneration
## Druggability Assessment
The NAD⁺-SIRT1-PGC1α axis presents **multiple actionable nodes**, but with varying tractability:
| Target | Druggability | Confidence Level |
|--------|--------------|-------------------|
| NAD⁺ precursors (NMN, NR) | High - oral bioavailability demonstrated | Clinical stage |
| SIRT1 activators | Moderate - mechanism debated, screening assays criticized | Preclinical/Phase I |
| PGC1α (transcriptional co-activator) | Low - intracellular, no enzymatic active site | Target identification |
| NAMPT activators | Low - rate-limiting enzyme, allosteric modulators scarce | Early discovery |
| CD38 inhibitors | Moderate - ecto-enzyme, small molecule feasible | Preclinical |
**Most advanced**: NAD⁺ precursor supplementation (nicotinamide riboside/NR, nicotinamide mononucleotide/NMN) represents the lowest-risk intervention. Human pharmacokinetics are established (PMID: 29238678).
## Competitive Landscape
**Companies with active programs**:
- **Elysium Health** - marketing Basis (NR+pterostilbene), completed Phase I safety trials (NCT02950441)
- **ChromaDex** - sponsors TRIIM trial (NR in elderly, completed)
- **Calico/Alipera** - developing NMN analogs
- **Sirtris/GSK** (acquired) - pursued resveratrol/sirtuin activators, failed in Phase II due to insufficient target engagement
- **Cohere/Regenxbio** - NAD⁺boost platform
**Key trial IDs**: NCT04228632 (NAD+ in Alzheimer's), NCT05086509 (NMN in Parkinson's), EUDRACT 2021-002171-39
## Cost/Timeline Estimates
- **Phase II efficacy**: 4-6 years, $15-30M per indication
- **NAD⁺ precursor repositioning**: 3-4 years with existing safety data
- **Novel NAMPT activators**: 7-10 years from scratch
## Critical Safety Concerns
1. **Pro-senescence vs. anti-senescence ambiguity** - SIRT1 has context-dependent roles; pan-SIRT1 activation may interfere with tumor suppression
2. **mTOR interaction** - NAD⁺ boosting may paradoxically activate mTORC1 through ATP increases
3. **Off-target sirtuins** - SIRT1-3 activators could disrupt cardiac metabolism
4. **Dosing J-curve** - rodent studies show narrow therapeutic windows
## Verdict
**Translational potential**: Moderate-high for NAD⁺ augmentation (low-risk repositioning), speculative for targeted senolytics. The mechanistic elegance masks a fundamental problem: we lack validated **in vivo biomarkers** of brain senescence. Without a translatable endpoint (e.g., p16 reporter PET ligands), Phase III设计中 will remain impossible. Recommend focusing on **CD38 inhibition** as an adjuvant strategy with cleaner selectivity.